UNSPSC 51383405: Proglumetacin dimaleate

This classification denotes an indoleacetic acid and non-steroidal anti-inflammatory agent with the molecular formula C46H58ClN5O8.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F2PUN24B8C, chemically known as 1h-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4-(3-((4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl)oxy)propyl)-1-piperazinyl)ethyl ester, (2z)-2-butenedioate (1:2), but more generally known as proglumetacin dimaleate, which bears US NIH Compound Identifier 6437391.

UNSPSC 51383405 Proglumetacin dimaleate, a Commodity code, shows little relevant recent activity under its nominal pharmaceutical-ingredient scope. The three recent opportunities tagged with this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals and OTC products — none of which align with proglumetacin dimaleate, a nonsteroidal anti-inflammatory drug ingredient. The code mismatch suggests that state and local procurement offices are either mis-tagging opportunities or that proglumetacin dimaleate itself does not drive solicitation activity in the state and local market at present.

The issuing bodies in the tagged opportunities include a county health agency (Seminole County, Florida), a state health commission (Texas Health and Human Services Commission), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance). Recent solicitations include an IFB for naloxone and drug deactivation systems from Seminole County with a due date of July 26, 2023, an RFI from Texas HHS posted April 3, 2026 seeking direct-to-manufacturer pharmacy program capabilities, and an RFP from MMCAP posted January 20, 2026 with a March 26, 2026 response date for generic pharmaceuticals and OTC products distributed through authorized wholesalers. The geographic spread covers Florida, Texas, and Minnesota with cross-state participation through MMCAP. Because the code's nominal scope and the actual solicitation content diverge substantially, business development professionals should verify the correct UNSPSC classification for proglumetacin dimaleate ingredients before pursuing opportunities in this space or treat recent activity under this code as a signal of mis-classification rather than market demand.